Rocket Pharmaceuticals Inc (RCKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $241.19M
Last updated: Nov 17, 2026 at 4:15 PM ET
Rocket Pharmaceuticals Inc (RCKT) Statistics
Rocket Pharmaceuticals (RCKT) has a market cap of $241.19M and an enterprise value of $176.14M. Revenue fell 100.00% over the last 12 months from the 12 months before. It holds $65.04M more cash than debt, 26.97% of its market cap.
Total Valuation
Enterprise value is 26.97% below the market cap, as cash exceeds debt.
| Market Cap | $241.19M |
|---|---|
| Enterprise Value | $176.14M |
| Latest price (Nov 17, 2026) | $2.11 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| Forward P/S | 261.9x |
|---|---|
| P/B Ratio | 0.7x |
| P/TBV Ratio | 0.9x |
Price Statistics
The stock is down 30.82% over 52 weeks and trades 20.38% below its 50-day average.
| Beta (1Y) | 1.79 |
|---|---|
| 52-Week Change | -30.82% |
| 1-Month Change | -5.80% |
| 3-Month Change | -42.19% |
| 6-Month Change | -27.74% |
| 5-Year Change | -91.79% |
| 10-Year Change | -91.29% |
| Total Return (1Y) | -30.82% |
| Total Return (3Y CAGR) | -54.18% |
| Total Return (5Y CAGR) | -39.99% |
| Return vs SPY (1Y) | -39.79% |
| Max Drawdown (1Y) | -60.19% |
| Max Drawdown (3Y) | -93.39% |
| Sharpe Ratio (1Y) | -0.48 |
| Correlation with SPY (1Y) | 0.36 |
| 50-Day Average | $2.65 |
| 200-Day Average | $3.38 |
| 52-Week Range | $2.15 to $5.45 |
| RSI (14 Days) | 35.6 |
| Average Volume (20 Days) | 1.65M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.26x current liabilities, and total debt is 0.09x shareholder equity.
| Current Ratio | 7.26x |
|---|---|
| Quick Ratio | 7.25x |
| Debt / Equity | 0.09x |
| Interest Coverage | -5.41x |
Returns and Efficiency
Return on invested capital is -2.26% over the last 12 months, against a 5-year average of -66.04%.
| Return on Equity (ROE) | -4.94% |
|---|---|
| Return on Assets (ROA) | -3.85% |
| Return on Invested Capital (ROIC) | -2.26% |
| ROE (5Y Average) | -53.74% |
| ROA (5Y Average) | -46.83% |
| ROIC (5Y Average) | -66.04% |
Scores
RCKT has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$190.36M |
| Pretax Income | -$9.91M |
| Net Income | -$16.15M |
| EBITDA | -$2.83M |
| Reported EPS (TTM) | -$1.38 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 77.88% of the $419.50M in total assets.
| Cash and Equivalents | $95.47M |
|---|---|
| Total Debt | $30.43M |
| Net Cash | $65.04M |
| Net Cash Per Share | $0.57 |
| Working Capital | $239.73M |
| Shareholder Equity | $326.72M |
| Book Value Per Share | $2.87 |
| Tangible Book Value | $262.42M |
| Tangible Book Per Share | $2.31 |
| Total Assets | $419.50M |
| Total Liabilities | $92.78M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $332.00K of capital spending, operating cash flow left -$159.23M of free cash flow.
| Operating Cash Flow | -$158.90M |
|---|---|
| Capital Expenditures | $332.00K |
| Free Cash Flow | -$159.23M |
| FCF Per Share | -$1.45 |
| Depreciation and Amortization | $8.51M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -34.77% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -38.69% |
Dividends and Yields
RCKT does not pay a dividend. Its free cash flow yield is -66.40%.
| FCF Yield | -66.40% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-4 reverse split on Jan 5, 2018.
| Last Split Date | Jan 5, 2018 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:4 |
Peer Position
Against 4 similar companies, RCKT has the highest ROIC.
ROICPeer median -76.25%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -75.60%
| ROIC | -2.26% vs -76.25% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -75.60% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RCKT
What is RCKT's market cap?
Rocket Pharmaceuticals has a market cap of $241.19M. Its enterprise value, which adds debt and subtracts cash, is $176.14M.
How many shares of RCKT are outstanding?
Rocket Pharmaceuticals has 113.65M shares outstanding. The count is up 1.86% from a year earlier.
Does RCKT pay a dividend?
No. Rocket Pharmaceuticals does not pay a dividend.
How much debt does RCKT have?
Rocket Pharmaceuticals has $30.43M of total debt and $95.47M of cash and equivalents, a net cash position of $65.04M.
RCKT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors